ConductScience.org, home

Paper31258425

Curative Therapies for Sickle Cell Disease.

Khemani K and 2 others. Ochsner J, 2019. Cited by 27 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Curative Therapies for Sickle Cell Disease. Papers, record 31258425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31258425

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Curative Therapies for Sickle Cell Disease.
PubMed
Journal
Ochsner J
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.25
iCite
Revised in PubMed
2020-10-01
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Khemani KKirshma
2Katoch DDeeksha
3Krishnamurti LLakshmanan

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110,706,855Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease.Blood2000https://conductscience.org/library/papers/10706855PubMed
211,607,766Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions.Bone Marrow Transplant2001https://conductscience.org/library/papers/11607766PubMed
312,424,197Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease.Blood2003https://conductscience.org/library/papers/12424197PubMed
4136,605Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection.N Engl J Med1977https://conductscience.org/library/papers/136605PubMed
517,250,455Hematopoietic cell transplantation for sickle cell disease: state of the art.Expert Opin Biol Ther2007https://conductscience.org/library/papers/17250455PubMed
617,560,447Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.Lancet2007https://conductscience.org/library/papers/17560447PubMed
717,606,762Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.Blood2007https://conductscience.org/library/papers/17606762PubMed
817,910,640Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.Br J Haematol2007https://conductscience.org/library/papers/17910640PubMed
918,489,989HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18489989PubMed
1018,640,578Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18640578PubMed
1118,721,780National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18721780PubMed
1219,074,070Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices.Hematology Am Soc Hematol Educ Program2008https://conductscience.org/library/papers/19074070PubMed
1319,822,218Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.Biol Blood Marrow Transplant2010https://conductscience.org/library/papers/19822218PubMed
1419,903,897The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).Blood2010https://conductscience.org/library/papers/19903897PubMed
1520,331,952Population estimates of sickle cell disease in the U.S.Am J Prev Med2010https://conductscience.org/library/papers/20331952PubMed
1620,513,116The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.Am J Hematol2010https://conductscience.org/library/papers/20513116PubMed
1720,940,417Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease.Blood2011https://conductscience.org/library/papers/20940417PubMed
1821,139,309The seventh sickle cell nephropathy.Intern Med2010https://conductscience.org/library/papers/21139309PubMed
1921,264,908Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium.Am J Hematol2011https://conductscience.org/library/papers/21264908PubMed
2021,277,376Umbilical cord blood transplantation for children with thalassemia and sickle cell disease.Biol Blood Marrow Transplant2011https://conductscience.org/library/papers/21277376PubMed

See all 47 references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42,486,917
Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations.
Bone Marrow Transplant2026https://conductscience.org/library/papers/42486917PubMed
41,387,179Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions.Immunology2026https://conductscience.org/library/papers/41387179PubMed
41,211,267Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas Unleashed: Transforming Gene Editing With Breakthroughs, Applications, and Ethical Dilemmas.Cureus2025https://conductscience.org/library/papers/41211267PubMed
40,311,069Use of the microfluidic impedance red cell assay in sickle cell disease.Blood Adv2025https://conductscience.org/library/papers/40311069PubMed
39,705,613Cerebral Hemodynamic Responses to Disease-Modifying and Curative Sickle Cell Disease Therapies.Neurology2025https://conductscience.org/library/papers/39705613PubMed
39,701,291Lipid Levels Increase to the Normal Range After Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease.Transplant Cell Ther2025https://conductscience.org/library/papers/39701291PubMed
39,443,591Development of a quantitative prediction algorithm for human cord blood-derived CD34+ hematopoietic stem-progenitor cells using parametric and non-parametric machine learning models.Sci Rep2024https://conductscience.org/library/papers/39443591PubMed
39,414,860Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease.Sci Rep2024https://conductscience.org/library/papers/39414860PubMed
39,359,845Advancing life: innovative approaches to enhance survival in sickle cell anemia patients.Ann Med Surg (Lond)2024https://conductscience.org/library/papers/39359845PubMed
38,972,510Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation.Transplant Cell Ther2024https://conductscience.org/library/papers/38972510PubMed
37,082,003Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives.J Blood Med2023https://conductscience.org/library/papers/37082003PubMed
37,069,266Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice.Nat Biomed Eng2023https://conductscience.org/library/papers/37069266PubMed
36,399,071Kruppel-like factor 1-GATA1 fusion protein improves the sickle cell disease phenotype in mice both in vitro and in vivo.Blood2022https://conductscience.org/library/papers/36399071PubMed
34,200,975Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.Int J Mol Sci2021https://conductscience.org/library/papers/34200975PubMed
33,407,701Bone fragility in patients affected by congenital diseases non skeletal in origin.Orphanet J Rare Dis2021https://conductscience.org/library/papers/33407701PubMed
33,213,986Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization.Blood Rev2021https://conductscience.org/library/papers/33213986PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31258425

GET https://conductscience.org/api/papers/v1/31258425/references?page=2